drugset
drugset / Trial / NCT00619619

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619 ↗

Phase 2 Completed 59 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupOpen-label

Summary

The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder. This study will also characterize the pharmacokinetic profile of DVS SR in children and adolescents with major depressive disorder.

Timeline

Start
2008-02
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 10 mg —
Subject Desvenlafaxine Other / unclassified 25 mg —
Subject Desvenlafaxine Other / unclassified 50 mg —
Subject Desvenlafaxine Other / unclassified 100 mg —
Subject Desvenlafaxine Other / unclassified 200 mg —

Indications

major depressive disorder